BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 16628961)

  • 1. [Drug safety of NSAIDs and COX-2 inhibitors].
    Herdegen T; Fauler J
    Med Monatsschr Pharm; 2006 Apr; 29(4):122-8. PubMed ID: 16628961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
    Hermann M; Ruschitzka F
    Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain].
    Nurmohamed MT
    Ned Tijdschr Geneeskd; 2007 Jun; 151(23):1313; author reply 1313-4. PubMed ID: 17624165
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular risks of cyclooxygenase inhibition.
    Stacy ZA; Dobesh PP; Trujillo TC
    Pharmacotherapy; 2006 Jul; 26(7):919-38. PubMed ID: 16803424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [COX-2 Inhibitors for the management of postoperative pain].
    Schug SA
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2010 Jan; 45(1):56-63. PubMed ID: 20091477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiovascular toxicity of selective COX-2-inhibitors and classical NSAIDs].
    Lange H; Eberhart L
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2007 Jul; 42(7):514-7. PubMed ID: 17661262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
    Vardeny O; Solomon SD
    Cardiol Clin; 2008 Nov; 26(4):589-601. PubMed ID: 18929233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs.
    Scheiman JM
    Gastroenterol Clin North Am; 2009 Jun; 38(2):305-14. PubMed ID: 19446260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].
    van den Bemt BJ; Benraad HB; Rasker JJ
    Ned Tijdschr Geneeskd; 2007 May; 151(19):1062-7. PubMed ID: 17552414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal.
    Hinz B; Renner B; Brune K
    Nat Clin Pract Rheumatol; 2007 Oct; 3(10):552-60; quiz 1 p following 589. PubMed ID: 17906610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
    Hur C; Chan AT; Tramontano AC; Gazelle GS
    Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs.
    Farkouh ME; Greenberg BP
    Am J Cardiol; 2009 May; 103(9):1227-37. PubMed ID: 19406264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Solomon SD
    Curr Opin Cardiol; 2006 Nov; 21(6):613-7. PubMed ID: 17053413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What price pain relief?
    Hochman JS; Shah NR
    Circulation; 2006 Jun; 113(25):2868-70. PubMed ID: 16785335
    [No Abstract]   [Full Text] [Related]  

  • 16. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The murky waters of the coxibs: a review of the current state of play.
    Ostor AJ; Hazleman BL
    Inflammopharmacology; 2005; 13(4):371-80. PubMed ID: 16354390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
    Joshi GP; Gertler R; Fricker R
    Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do steroids, conventional non-steroidal anti-inflammatory drugs and selective Cox-2 inhibitors adversely affect fracture healing?
    Boursinos LA; Karachalios T; Poultsides L; Malizos KN
    J Musculoskelet Neuronal Interact; 2009; 9(1):44-52. PubMed ID: 19240368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.